Attenuation of psilocybin mushroom effects during and after SSRI/SNRI antidepressant use
In a retrospective survey of psilocybin mushroom users, serotonergic antidepressants (SSRIs, SNRIs) were associated with substantially higher odds of weakened psilocybin effects—about 47% for SSRIs and 55% for SNRIs versus 29% for the non‑serotonergic antidepressant bupropion—and this attenuation persisted for up to three months after discontinuation. Sensitivity analysis excluding fluoxetine did not materially change the post‑discontinuation result.
Authors
- Roland Griffiths
- Sandeep Nayak
- David Yaden
Published
Abstract
Background
Psilocybin is being studied for depression, but little is known about how it interacts with common antidepressants. Limited data suggest that psilocybin’s effects may be diminished by serotonergic antidepressants acutely and even after a medication washout period.
Aims
To learn the extent to which antidepressants may diminish the effects of psilocybin-containing mushrooms both concurrently and after discontinuation of antidepressants.
Methods
Online retrospective survey of individuals with use of psilocybin mushrooms (1) with an antidepressant and/or (2) within 2 years of discontinuing an antidepressant. Participants who took mushrooms with an antidepressant and either took the same dose pre-antidepressant or took the same dose with other people not on antidepressant reported the strength of drug effects relative to their expectation. Participants who took mushrooms following discontinuation of an antidepressant also reported the presence of weakened effects.
Results
In reports ( n = 611) of taking mushrooms with an antidepressant, probabilities [95% CI] of weaker than expected drug effects were 0.47 [0.41–0.54] (selective serotonergic reuptake inhibitors, SSRIs), 0.55 [0.44–0.67] (serotonin norepinephrine reuptake inhibitors, SNRIs) and 0.29 [0.2–0.39] (bupropion). Following SSRI/SNRI discontinuation ( n = 1,542 reports), the probability of reduced drug effects was not significantly different from the earliest post-discontinuation timepoint (within 1 week) until 3–6 months, probability = 0.3 [0.20–0.46], p = 0.001. A sensitivity analysis found that removing responses involving fluoxetine, which has an especially long half-life, did not significantly alter this result.
Conclusions
SSRI/SNRIs appear to weaken psilocybin drug effects relative to a non-serotonergic antidepressant. This dampening effect may last as long as 3 months following antidepressant discontinuation.
Research Summary of 'Attenuation of psilocybin mushroom effects during and after SSRI/SNRI antidepressant use'
Introduction
Gukasyan and colleagues situate the study within growing interest in psilocybin-assisted therapy for major depressive disorder, noting that clinical trials commonly require discontinuation of serotonergic antidepressants prior to psychedelic administration. Prior reports—largely from LSD studies, small clinical samples, and anecdotal sources—have suggested that monoaminergic antidepressants, particularly SSRIs and MAOIs, can attenuate classic psychedelic effects or, conversely, sometimes potentiate them depending on the drug class. There is also theoretical concern about interactions such as serotonin syndrome, but empirical data on psilocybin specifically are limited and mixed. The study therefore aimed to quantify two practical questions in a large naturalistic sample: (1) whether taking an antidepressant concurrent with psilocybin-containing mushrooms is associated with reduced subjective drug intensity, and (2) whether any reduction in subjective intensity persists after discontinuation of antidepressants and for how long. The investigators also collected data on self-reported adverse events, including possible serotonin syndrome. The work is a retrospective online survey intended to capture naturalistic experiences across a broad population of mushroom users with recent or concurrent antidepressant exposure.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Study Details
- Study Typeindividual
- Journal
- Compound
- Topics
- Authors
- APA Citation
Gukasyan, N., Griffiths, R. R., Yaden, D. B., Antoine, D. G., & Nayak, S. M. (2023). Attenuation of psilocybin mushroom effects during and after SSRI/SNRI antidepressant use. Journal of Psychopharmacology, 37(7), 707-716. https://doi.org/10.1177/02698811231179910
References (14)
Papers cited by this study that are also in Blossom
Becker, A. M., Holze, F., Grandinett, T. et al. · Clinical Pharmacology and Therapeutics (2021)
Bonson, K. R. · Neuropsychopharmacology (1996)
Carhart-Harris, R. L., Bolstridge, &. M., Day, C. M. J. et al. · Psychopharmacology (2017)
Goodwin, G. M., Aaronson, S. T., Alvarez, O. et al. · New England Journal of Medicine (2022)
Griffiths, R. R. · Journal of Psychopharmacology (2008)
Davis, A. K., Streeter Barrett, F., Cosimano, M. P. et al. · Journal of Psychopharmacology (2022)
Madsen, M. K., Fisher, P. M., Burmester, D. et al. · Neuropsychopharmacology (2019)
Malcolm, B., Thomas, K. · Psychopharmacology (2021)
Nayak, S., Gukasyan, N., Barrett, F. S. et al. · Pharmacopsychiatry (2021)
Nichols, D. E. · Pharmacology and Therapeutics (2004)
Show all 14 referencesShow fewer
Nichols, D. E. · Pharmacological Reviews (2016)
Rickli, A., Moning, O. D., Hoener, M. C. et al. · European Neuropsychopharmacology (2016)
Roseman, L., Nutt, D. J., Carhart-Harris, R. L. · Frontiers in Pharmacology (2018)
Sarparast, A., Thomas, K., Malcolm, B. et al. · Psychopharmacology (2022)
Cited By (11)
Papers in Blossom that reference this study
Seynaeve, M., Dunbar, F., Hindocha, C. et al. · CNS Drugs (2026)
O’Mahony, B., Harrington, C., Harkin, A. et al. · Journal of Psychopharmacology (2026)
Henningfield, J. E., Barrett, F. S., Evans, S. M. et al. · Journal of Psychopharmacology (2026)
Chisamore, N., Kaczmarek, E. S., Doyle, Z. et al. · Canadian Journal of Psychiatry (2025)
Becker, A. M., Humbert-Droz, M., Mueller, L. et al. · Clinical Pharmacology and Therapeutics (2025)
Marwood, L., Croal, M., Mistry, S. et al. · Journal of Psychiatric Research (2024)
Erritzoe, D., Barba, T., Spriggs, M. J. et al. · Journal of Psychopharmacology (2024)
Siva, J. B., Barba, T., Kettner, H. et al. · Journal of Psychopharmacology (2024)
Halman, A., Kong, G., Sarris, J. et al. · Journal of Psychopharmacology (2023)
Nayak, S., Jackson, H., Sepeda, N. D. et al. · Frontiers in Psychiatry (2023)
Show all 11 papersShow fewer
Goodwin, G. M., Croal, M., Feifel, D. et al. · Neuropharmacology (2023)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.